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Cantu syndrome (CS) is characterized by multiple vascular and cardiac abnormalities
including vascular dilation and tortuosity, systemic hypotension, and cardiomegaly. The
disorder is caused by gain-of-function (GOF) mutations in genes encoding pore-forming
(Kir6.1, KCNJ8) and accessory (SUR2, ABCC9) ATP-sensitive potassium (KATP) channel
subunits. However, there is little understanding of the link between molecular dysfunction
and the complex pathophysiology observed, and there is no known treatment, in large part
due to the lack of appropriate preclinical disease models in which to test therapies. Notably,
expression of Kir6.1 and SUR2 does not fully overlap, and the relative contribution of KATP
GOF in various cardiovascular tissues remains to be elucidated. To investigate
pathophysiologic mechanisms in CS we have used CRISPR/Cas9 engineering to introduce
CS-associated SUR2[A478V] and Kir6.1[V65M] mutations to the equivalent endogenous
loci in mice. Mirroring human CS, both of these animals exhibit low systemic blood pressure
and dilated, compliant blood vessels, as well dramatic cardiac enlargement, the effects
being more severe in V65M animals than in A478V animals. In both animals, whole-cell
patch-clamp recordings reveal enhanced basal KATP conductance in vascular smooth
muscle, explaining vasodilation and lower blood pressure, and demonstrating a cardinal
role for smooth muscle KATP dysfunction in CS etiology. Echocardiography confirms in situ
cardiac enlargement and increased cardiac output in both animals. Patch-clamp recordings
reveal reduced ATP sensitivity of […]
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Introduction
Cantu syndrome (CS) was first recognized as a distinct pathology 35 years ago (1). The syndrome is 
extremely complex, with patients typically demonstrating a host of  cardiovascular features including 
marked cardiomegaly, vascular dilation and tortuosity, low blood pressure, persistence of  fetal circulation, 
and pulmonary hypertension (2–6), in addition to hypertrichosis and acromegaloid facial features (7, 8). 
The molecular basis is now clear: CS results from mutations in the ABCC9 and KCNJ8 genes, which encode 
the regulatory ABCC9 (SUR2) sulfonylurea receptor and pore-forming KCNJ8 (Kir6.1) subunits, respec-
tively, of  ATP-sensitive potassium (KATP) channels (9–12). Expressed in various tissues in the body, KATP 
channels are nucleotide-gated, potassium-selective channels that couple cellular metabolism to electrical 
excitability. KCNJ8 and ABCC9 are adjacent genes on human chromosome 12p12.1, and there is a paralo-
gous pair of  genes (KCNJ11 [Kir6.2] and ABCC8 [SUR1]) on chromosome 11p15.1, with the consequence 
that multiple subunit combinations may be present in KATP channels in different tissues. Heterogeneity is 
further increased by the existence of  variably spliced SUR isoforms; particularly prominent are 2 major 
splice isoforms of  SUR2: SUR2A and SUR2B (13–15). KATP channels in vascular smooth muscle are pre-
dominantly formed of  Kir6.1 and SUR2B, and regulate vascular tone and blood pressure (16, 17), whereas 
Kir6.2 and SUR2A predominate in cardiac ventricular myocytes, wherein channel activation can result in 
Cantu syndrome (CS) is characterized by multiple vascular and cardiac abnormalities including 
vascular dilation and tortuosity, systemic hypotension, and cardiomegaly. The disorder is 
caused by gain-of-function (GOF) mutations in genes encoding pore-forming (Kir6.1, KCNJ8) and 
accessory (SUR2, ABCC9) ATP-sensitive potassium (KATP) channel subunits. However, there is 
little understanding of the link between molecular dysfunction and the complex pathophysiology 
observed, and there is no known treatment, in large part due to the lack of appropriate preclinical 
disease models in which to test therapies. Notably, expression of Kir6.1 and SUR2 does not fully 
overlap, and the relative contribution of KATP GOF in various cardiovascular tissues remains to 
be elucidated. To investigate pathophysiologic mechanisms in CS we have used CRISPR/Cas9 
engineering to introduce CS-associated SUR2[A478V] and Kir6.1[V65M] mutations to the equivalent 
endogenous loci in mice. Mirroring human CS, both of these animals exhibit low systemic blood 
pressure and dilated, compliant blood vessels, as well dramatic cardiac enlargement, the effects 
being more severe in V65M animals than in A478V animals. In both animals, whole-cell patch-
clamp recordings reveal enhanced basal KATP conductance in vascular smooth muscle, explaining 
vasodilation and lower blood pressure, and demonstrating a cardinal role for smooth muscle KATP 
dysfunction in CS etiology. Echocardiography confirms in situ cardiac enlargement and increased 
cardiac output in both animals. Patch-clamp recordings reveal reduced ATP sensitivity of ventricular 
myocyte KATP channels in A478V, but normal ATP sensitivity in V65M, suggesting that cardiac 
remodeling occurs secondary to KATP overactivity outside of the heart. These SUR2[A478V] and 
Kir6.1[V65M] animals thus reiterate the key cardiovascular features seen in human CS. They 
establish the molecular basis of the pathophysiological consequences of reduced smooth muscle 
excitability resulting from SUR2/Kir6.1–dependent KATP GOF, and provide a validated animal model 
in which to examine potential therapeutic approaches to treating CS.
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significant shortening of  the ventricular action potential, which may be cardioprotective in conditions of  
metabolic or ischemic stress (18, 19).
All identified Kir6.1 and SUR2 CS mutations result in enhanced activity of  recombinant KATP channels 
(20–23) and are therefore expected to result in KATP GOF in vivo, although this has not been established. 
Channel GOF is in turn predicted to result in hyperpolarization of  the membrane potential and thus a 
primary decrease of  excitability, in all relevant cell types. In smooth muscle, decreased excitability would 
be predicted to cause vasorelaxation and lowering of  blood pressure. In the myocardium, the naive predic-
tion of  KATP overactivity would be reduced action potential duration, shortening of  the QT interval, and 
reduced contractility as a consequence. How KATP overactivity results in the complex and diverse patho-
physiology of  CS is not trivially obvious and remains largely unexplained. Here, we report the generation 
of  CRISPR/Cas9–modified mice in which CS-associated mutations were introduced into native KCNJ8 
and ABCC9 loci. These animals establish that both primary and secondary cardiovascular features of  CS 
specifically arise from consequences of  GOF missense mutations in Kir6.1 and SUR2, and inform the con-
sequences of  vascular smooth muscle inexcitability more generally.
Results
Generation of  CRISPR/Cas9–modified KCNJ8- and ABCC9-mutant mice. CS arises from GOF mutations in 
KCNJ8 and ABCC9, the genes encoding the KATP channel subunits, Kir6.1 and SUR2, respectively. CRISPR/
Cas9 gene editing was used to introduce single-nucleotide mutations into the endogenous KCNJ8 and ABCC9 
gene loci, resulting in protein substitutions that are analogous to Kir6.1[V65M] (V65M in mouse sequence) 
and SUR2[A478V] (A476V in mouse sequence) in human CS patients (Figure 1, A and B; see Methods).
Founder animals were all viable and fertile, and were bred back to C57BL/6J WT mice to establish 
several heterozygous lines of  each genotype. Homozygous and heterozygous animals from generations F3 
onwards were analyzed in all experiments below. There was a minor decrease in survival for heterozygous 
Kir6.1[V65M] (Kir6.1wt/VM), heterozygous SUR2[A478V] mice (SUR2wt/AV), and homozygous SUR2[A478V] 
(SUR2AV/AV) mice (Figure 1C). Crossing heterozygous animals from the 2 mutant lines also yielded double-
heterozygous Kir6.1wt/VM/SUR2wt/AV mice, which showed markedly increased mortality (Figure 1C). Survival 
was drastically decreased in homozygous Kir6.1VM/VM mice (Figure 1C), which consistently lost weight prior 
to dying, within a week or so after weaning (Figure 1D). Autopsy of  Kir6.1VM/VM mice sacrificed at 3 weeks 
Figure 1. Generation of the Cantu mice. (A) 
Left: Structural representation of the pancreatic 
Kir6.2/SUR1 KATP channel (PDB ID: 5WUA) with 
the equivalent position of Kir6.1[V65M] and 
SUR2[A478V] highlighted. Right: Predominant 
isoform composition of vascular smooth muscle 
(Kir6.1/SUR2B) and ventricular (Kir6.2/SUR2A) 
KATP channels. (B) Sequencing chromatograms 
from heterozygous Kir6.1wt/VM and SUR2wt/AV ani-
mals. (C) Kaplan-Meier survival curves for WT 
and Cantu animals (n = 8–25 in each genotype). 
(D) Body weight measurements from Kir6.1wt/VM,  
Kir6.1VM/VM, and WT littermate mice prior to 
weaning; Kir6.1VM/VM mice lose weight prior 
to premature death at around 20 days (n = 
15–25 animals). Statistical significance was 
determined by multiway ANOVA followed by 
t test pairwise comparison with Bonferroni’s 
correction for multiple comparisons (adjusted α 
= 0.05/3 = 0.017). *P < 0.05.
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of age revealed distended intestines which, when considered alongside the observed weight loss, may indicate 
impaired gastrointestinal function.
Mutation of  Kir6.1 and SUR2 results in GOF of  native vascular smooth muscle KATP channels, but ventricular myocyte 
KATP is only affected in SUR2-mutant mice. The effects of the introduced mutations on KATP channel function were 
determined using patch-clamp electrophysiology. Firstly, whole-cell patch-clamp recordings, using an intracel-
lular pipette solution containing no ATP (see Methods), revealed a markedly higher (~5-fold) basal potassium 
conductance in acutely isolated aortic smooth muscle cells from Kir6.1wt/VM mice, compared with WT (Figure 
2, A and C). Application of the KATP channel opener, pinacidil, provoked significant increase in conductance in 
WT vascular smooth muscle cells (VSMCs), but this effect was blunted in VSMCs from V65M mice, reflecting 
basal activation of the mutant KATP channels. Subsequent application of the KATP channel inhibitor, gliben-
clamide, markedly reduced the pinacidil-activated conductance in WT VSMCs, but was less effective in V65M 
(Figure 2, A and C), potentially reflecting the reduced glibenclamide sensitivity of Kir6.1[V65M] channels 
(21). Importantly, inclusion of a high concentration (5 mM) of ATP in the patch pipette essentially abolished 
both basal and pinacidil-activated conductances in cells from both WT and V65M VSMCs (Figure 2, B and C), 
confirming that the observed conductances resulted from KATP channel activity.
Because homozygous SUR2AV/AV mice survive to adulthood, we were able to analyze the effect of  
the SUR2[A478V] mutation in both heterozygous SUR2wt/AV and homozygous SUR2AV/AV mice. In both 
Figure 2. Smooth muscle KATP channels 
in Kir6.1wt/VM and SUR2wt/AV  
mice. (A) Representative whole-cell 
voltage-clamp recordings from acutely 
isolated aortic smooth muscle cells 
from WT (top) and Kir6.1wt/VM (bottom) 
mice. Cells were voltage clamped at 
–70 mV. (B) Representative whole-
cell voltage-clamp recordings from 
Kir6.1wt/VM aortic smooth muscle cells 
using an intracellular pipette solution 
containing 5 mM ATP. (C) Summary 
of whole-cell current densities from 
voltage-clamp recordings of Kir6.1wt/VM 
aortic smooth muscle cells showing sig-
nificant increases in basal and pinacidil-
activated KATP conductances, which are 
resistant to glibenclamide inhibition 
(n ≥ 5 for WT and 11 for Kir6.1wt/VM from 
≥ 3 mice each). (D) Representative 
whole-cell voltage-clamp recordings 
from acutely isolated aortic smooth 
muscle cells from WT (left, black), het-
erozygous SUR2wt/AV (middle, orange), 
and homozygous SUR2AV/AV (right, red) 
mice using an intracellular pipette 
solution absent of nucleotides (–70 mV 
holding potential). (E) Left: Summary 
of whole-cell current densities from 
voltage-clamp recordings of aortic 
smooth muscle cells from WT, SUR2wt/AV, 
and SUR2AV/AV mice showing significant 
increases in basal and pinacidil-activat-
ed KATP conductances (n ≥ 8 for WT, 11 
for SUR2wt/AV, and 14 for SUR2AV/AV from ≥ 
3 mice each). Right: Summary of experi-
ments in which 5 mM ATP was included 
in the patch pipette shown for WT and 
SURAV/AV cells. Statistical significance 
was determined by multiway ANOVA 
followed by t test pairwise comparison 
with Bonferroni’s correction for multiple 
comparisons. Adjusted α = 0.008 (C) 
and 0.003 (E). **P < 0.01.
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cases, basal KATP activation was also increased in whole-cell patch-clamp recordings from isolated VSMCs 
(~1.5-fold and ~2.2-fold increases for SUR2wt/AV and SUR2AV/AV, respectively) (Figure 2, D and E). Glib-
enclamide reduced currents to near basal levels and, again, inclusion of  5 mM ATP in the pipette solu-
tion abolished basal K+ conductances (Figure 2E), confirming that the increase observed in SUR2[A478V] 
VSMCs was due to elevated basal KATP activity. Notably, the KATP GOF in VSMCs from both SUR2
wt/AV 
and SUR2AV/AV mice was less than that observed in Kir6.1wt/VM mice, which is consistent with the effect of  
these 2 substitutions in recombinantly expressed KATP channels (21, 24).
Nucleotide regulation of  native KATP channels in the heart was assessed using excised, inside-out 
patch-clamp recordings from acutely dissociated ventricular myocytes. Consistent with the prevailing evi-
dence that ventricular KATP channels are composed predominantly of  Kir6.2/SUR2A subunits (i.e., that 
Kir6.1 is not present in these channels), there was no difference between sensitivity of  WT or V65M chan-
nel activity to MgATP (Figure 3, A and B), which provides a combined assessment of  ATP inhibition and 
Mg-nucleotide activation of  channels. In contrast, excised patch-clamp recordings from SUR2wt/AV and 
SUR2AV/AV ventricular myocytes revealed right-shifted MgATP sensitivity (~2- and ~3.5-fold increases in 
IC50, respectively; Figure 3, C and D), as predicted, given that SUR2 is expressed in ventricular myocytes 
(15). Thus, in both VSMCs and ventricular myocytes a progressive increase in GOF was observed through 
heterozygous and homozygous SUR2[A478V] mice. Taken together, these data confirm the expected 
molecular consequences of  the Kir6.1[V65M] substitution, i.e., that it results in marked GOF of  VSMC 
KATP, but has no significant effect on cardiomyocyte KATP channels, whereas the SUR2[A478V] substitu-
tion results in GOF of  KATP channels in both VSMCs and ventricular myocytes.
We subsequently analyzed cellular, organ, and whole-animal phenotypes of  the different genotypes. 
Despite the above qualitatively different outcomes for ventricular KATP properties in the Kir6.1[V65M] 
and SUR2[A478V] animals, all of  the subsequent features described below were qualitatively similar in 
Figure 3. KATP channels in Kir6.1wt/VM and SUR2wt/AV ventricular myocytes. (A) Representative inside-out voltage-clamp recordings of KATP channel activ-
ity from acutely dissociated ventricular myocytes from WT (left) and Kir6.1wt/VM mice showing the response to MgATP (recording from –50 mV holding 
potential). (B) Summary [MgATP]-response curves from excised patch experiments (IC50 values from individual experiments shown in inset; n = 10 for WT 
and Kir6.1wt/VM from ≥ 3 mice each). (C) Representative inside-out voltage-clamp recordings of KATP channel activity from acutely dissociated ventricular 
myocytes from WT (left, black), SUR2wt/AV (middle, orange), and SUR2AV/AV (right, red) mice showing the response to MgATP (recording from –50 mV holding 
potential). (D) Summary MgATP dose-response curves from excised patch experiments shows increased MgATP IC50 in SUR2wt/AV and SUR2AV/AV mice (IC50 
values from individual experiments shown in inset; n = 7 from WT, 9 from SUR2wt/AV, and SUR2AV/AV, from ≥ 3 mice each). Statistical significance was deter-
mined by multiway ANOVA followed by t test pairwise comparison with Bonferroni’s correction for multiple comparisons (adjusted α = 0.017). *P < 0.05.
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both Kir6.1[V65M] and SUR2[A478V] animals, but they were more marked in the former. Therefore, 
we first present in detail the findings from Kir6.1[V65M] animals, and then present parallel data from the 
SUR2[A478V] animals.
Vascular consequences of  KATP GOF. CS patients exhibit dilated and tortuous blood vessels, reduced 
blood pressure, and decreased pulse wave-velocity (4, 25), suggestive of  a chronically relaxed, compliant 
vasculature. In Kir6.1wt/VM mice, marked changes in gross vascular structure were observed, including sig-
nificantly increased aortic diameters (ranging from ~15% to 70% increases around the proximal aorta, not 
significant at the aortic arch), as measured in vivo by echocardiographic imaging and directly on isolated 
tissue (Figure 4A). Assessment of  pressurized carotid arteries, reflecting noncontractile biomechanical 
properties of  the vessels, revealed significantly increased arterial diameters across the full range of  physi-
ological pressures, and increased compliance (Figure 4B).
Marked reduction (~20–25 mmHg) of both systolic and diastolic basal blood pressures were observed 
in anesthetized 3-month-old Kir6.1wt/VM mice (Figure 4C). Acute administration of pinacidil, which reduces 
Figure 4. The effects of KATP gain of function on vascular structure and function in Kir6.1wt/VM. (A) Left: Isolated 
descending thoracic aortas show significant gross enlargement in Kir6.1wt/VM (middle). Sagittal 2D echocardiographic 
images of the aortic arch reveal significant dilation in Kir6.1wt/VM mice (aortic boundaries indicated by dashed lines). 
Right: Measurements of aortic diameter derived from 2D sagittal echocardiographic imaging at different points around 
the aortic arch in WT (black) and Kir6.1wt/VM mice (blue). STJ, sinotubular junction; AA, ascending aorta; Arch, aortic arch; 
DA, descending aorta; as shown in inset; n = 5). (B) Vessel compliance measurements from pressurized carotid arteries 
of WT (black) and Kir6.1wt/V (blue) mice (n = 4 for WT, n = 7 for Kir6.1wt/VM). (C) Representative blood pressure measure-
ments from anesthetized mice showing decreased basal systemic pressures in Kir6.1wt/VM mice and blunted response 
to the KATP channel activator pinacidil. (D) Summary data showing systolic (left) and diastolic (right) pressures from 
anesthetized mice (n = 9 for WT and 6 for Kir6.1wt/VM). (E) Telemetric measurements of mean arterial pressure from 
ambulatory WT and Kir6.1wt/VM mice (n = 5 for both WT and Kir6.1wt/VM). Statistical significance was determined by multi-
way ANOVA followed by t test pairwise comparison with Bonferroni’s correction for multiple comparisons. Adjusted α = 
0.013 (A), 0.007 (B), 0.013 (D), and 0.025 (E). *P < 0.05; **P < 0.01.
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blood pressure by activation of smooth muscle KATP in WT mice, was severely blunted in Kir6.1
wt/VM animals 
(Figure 4, C and D), reflective of the high basal KATP activity and consequently reduced additional activation by 
pinacidil that is seen in isolated VSMCs (Figure 2). In agreement with data from the anesthetized mice, ambu-
latory telemetric recordings also showed approximately 30-mmHg decreases in blood pressure in Kir6.1wt/VM 
mice at both night and day, although the difference was not significant during the daytime (Figure 4E).
Therefore, Kir6.1wt/VM mice display dilated, compliant arterial vessels resulting in hypotension, mirror-
ing clinical observations in CS patients (4, 25).
Cardiac hypertrophy in Cantu mice. Cardiomegaly is a consistent finding in CS patients (25) and is dra-
matically recapitulated in adult Kir6.1wt/VM mice, which show approximately 1.7-fold increases in heart 
weight (Figure 5A). Estimates of  ventricular myocyte size, both from cell capacitance, a correlate of  cell 
membrane surface area, in whole-cell patch clamp recordings of  isolated myocytes (Figure 5B), and from 
H&E-stained ventricular tissue cross sections (Figure 5C), indicate that the increased cardiac mass arises 
from equivalent cellular hypertrophy.
Echocardiographic imaging in vivo also demonstrates an approximately 2-fold increase in left ven-
tricle (LV) mass in Kir6.1wt/VM mice, with dilated LV chamber diameters (~30% increase) along with 
approximately equivalent increases in LV posterior wall and intraventricular septal thickness, compared 
Figure 5. Cardiac hypertrophy in the Kir6.1wt/VM mouse. (A) Left: Gross heart size is increased in Kir6.1wt/VM mice. 
Right: Heart weight normalized to tibia length (HW/TL; mg/mm; n = 11 for WT and 12 for Kir6.1wt/VM). (B) Cardiomeg-
aly results from cellular hypertrophy as indicated by increased cell capacitance (measured from whole-cell voltage-
clamp recordings of isolated ventricular myocytes (n = 11 for WT and 16 for Kir6.1wt/VM) and (C) from measurements 
of cell surface area (CSA) from H&E-stained ventricular tissue (n = 116 cells from 3 mice for WT and 69 cells from 3 
mice for Kir6.1wt/VM). (D) Parasternal long-axis echocardiographic imaging shows increased left ventricle (LV) internal 
diameter and wall thickness in Kir6.1wt/VM (endo- and epicardial boundaries indicated by white or blue lines for WT 
and Kir6.1wt/VM, respectively). (E) M-mode echocardiographic quantification of LV mass (LVM; far left), LV internal 
diameter (LVID; middle left), LV posterior wall (LVPW; middle right), and intraventricular septum (IVS; far right) 
are increased in Kir6.1wt/VM mice (n = 5 for both). Statistical significance determined by t test for A, C, and LVM (in 
E). For LVID, LVPW, and IVS in E, statistical significance was determined by multiway ANOVA followed by t test 
pairwise comparison with Bonferroni’s correction for multiple comparisons (adjusted α = 0.025). *P < 0.05.
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with WT (Figure 5, D and E). Consequently, relative wall thickness (RWT) was not significantly different 
in Kir6.1wt/VM mice (RWT for WT 0.57 ± 0.02 mm; for Kir6.1wt/VM 0.52 ± 0.03 mm; P = 0.1), although 
suggestive of  a mild prevailing eccentric hypertrophy.
Therefore, despite Kir6.1wt/VM cardiac myocytes showing essentially normal KATP channels, Kir6.1
wt/VM 
hearts display chamber dilation and marked cardiac enlargement as a result of  cellular hypertrophy, again 
consistent with echocardiographic findings in CS patients (3, 25).
Aortic regurgitation and stenosis in Kir6.1wt/VM mice. Cardiac hypertrophy can be associated with valvular 
defects and/or aortic insufficiency (AI), as has been reported in CS patients (2, 6). Aortic valve function 
was assessed in vivo by echocardiography. AI and aortic stenosis (AS) of  variable extent were observed in 
color Doppler echocardiographic imaging in 4 of  5 Kir6.1wt/VM mice, with 0 of  5 WT littermate controls 
affected (Figure 6, A and B). The extent of  AI was strongly correlated with the measured aortic diameter 
(sinotubular junction diameter, Figure 6C). In addition, relative AS was apparent in 4 of  5 Kir6.1wt/VM mice, 
in which qualitative valve thickening and restricted leaflet opening were observed (Figure 6, A and B). This 
was accompanied by elevated mean pressure gradients across the valve in the Kir6.1wt/VM mice (Figure 6, 
A and B, and Supplemental Video 1; supplemental material available online with this article; https://doi.
org/10.1172/jci.insight.121153DS1).
This combination of  AI and increased preload, alongside stenotic or dysfunctional valves with resul-
tant increases in afterload, could contribute to the LV hypertrophy and chamber dilation that are observed. 
However, there was only a weak correlation between AI or mean gradient and LV mass (Figure 6C), sug-
gesting that both AI and valvular defects may not be primary drivers of  hypertrophy in these mice.
Increased cardiac output in Kir6.1wt/VM mice. In echocardiographic recordings, fractional shortening was 
not different from WT, but cardiac output was dramatically (~65%) higher, due to equivalently greater 
stroke volume (Figure 7, A–E). There was a significantly (~80%) higher rate of  LV emptying (dV/dT max) 
Figure 6. Aortic insufficiency and aortic regurgitation in the 
Kir6.1wt/VM mouse. (A) Echocardiographic imaging in diastole reveals 
aortic valve insufficiency (AI; aortic regurgitation) in 4 of 5 Kir6.1wt/VM 
mice tested (AI not observed in any WT mice; n = 5), see also 
Supplemental Video 1. (B) 2D color Doppler echocardiographic imag-
ing in systole shows aortic valve stenosis in 4 of 5 Kir6.1wt/VM but 0 
of 5 WT mice (see also Supplemental Video). In A and B, statistical 
significance was determined by t test. *P < 0.05. (C) Correlation of 
AI with aortic diameter at the sinotubular junction (STJ) (left); left 
ventricular mass (LVM; derived from echocardiography) and aortic 
valve pressure gradient (middle); and LVM and AI area (right) in 
Kir6.1wt/VM mice. R denotes Pearson’s correlation coefficient.
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in Kir6.1wt/VM mice (Figure 7F). This combination of  features is consistent with the characteristic high-
output cardiac phenotype observed in CS patients (25) that is distinct from typical hypertrophic or dilated 
cardiomyopathies in which systolic function is impaired. It is consistent with earlier studies of  transgenic 
mice, which showed that expression of  KATP GOF subunits in either the myocardium or in VSM both result 
in hypercontractile phenotypes in the heart (25, 26). These outcomes are not directly predicted from any 
expected electrophysiological consequences of  cardiac KATP channel GOF. Baseline surface ECG record-
ings from ambulatory Kir6.1wt/VM mice were not markedly different from WT, consistent with patch-clamp 
studies of  isolated ventricular myocytes showing no major changes in Kir6.1wt/VM cardiac KATP function 
(Figure 3). Therefore, we suggest that the high-output, enlarged heart observed in Kir6.1wt/VM mice may 
result not from a primary effect on cardiac KATP but rather from systemic feedback mechanisms that coun-
ter hypotension arising from vascular KATP GOF.
Key CS features are common to both Kir6.1 and SUR2 GOF mutant mice. Basal systolic and diastolic 
blood pressures were also decreased relative to WT, in both anesthetized SUR2AV/AV and SUR2wt/AV mice. 
Ambulatory blood pressures also decreased in both, but only significantly so in SUR2AV/AV mice (Figure 
8, A and B). As seen in Kir6.1[V65M] animals, the relative blood pressure–lowering effect of  pinacidil 
was again reduced in SUR2wt/AV, and more so in SUR2AV/AV (Figure 8, A and C), to the extent that, 
intriguingly, the lowest pressure achieved with pinacidil was actually higher in SUR2wt/AV than WT, and 
even more so in SUR2AV/AV (Figure 8, A and C), the implications of  which are considered in the Discus-
sion. As observed in Kir6.1wt/VM mice, there were clear trends towards progressively increased vascular 
Figure 7. Cardiac function in WT and Kir6.1wt/VM mice. (A) Representative M-mode echocardiographic imaging of WT 
(top) and Kir6.1wt/VM mice (bottom) showing dilated left ventricle chambers and increased wall diameters. d, diastole; 
s, systole; IVS, interventricular septum; LVID, left ventricular internal diameter; LVPW, left ventricular posterior wall. 
(B) Left ventricle (LV) fractional shortening (FS) is unchanged in Kir6.1wt/VM as determined from M-mode echocardio-
grams (n = 5 for both). (C) Stroke volume (SV) is increased in Kir6.1wt/VM mice (n = 5 for both). (D) Heart rate (HR) is 
unchanged in lightly anesthetized Kir6.1wt/VM mice during echocardiographic investigation (n = 5 for both genotypes). 
(E) Cardiac output is markedly increased in Kir6.1wt/VM mice due to increased SV and preserved FS. (F) Peak myocar-
dial strain rate (dV/dT max) was increased in Kir6.1wt/VM mice as determined from speckle tracking measurements. 
(G) Left: Representative ECG recordings from awake WT (black) and Kir6.1wt/VM (blue) mice. Right: Summary HR, RR-
interval, QT duration, and corrected QT (QTc) from WT and Kir6.1wt/VM mice (data shown as mean ± SEM; n = 7 for WT, 
n=11 for Kir6.1wt/VM). Statistical significance determined by t test. *P < 0.05.
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diameters, both in vivo in echocardiographic imaging and ex vivo in pressurized compliance measure-
ments on isolated vessels, for SUR2wt/AV and SUR2AV/AV mice (Figure 8, D–F).
Marked cardiomegaly was also observed in both SUR2wt/AV and SUR2AV/AV mice (~1.2- and ~1.6-fold 
increases, respectively; Figure 9A), which cell surface area measurements again revealed to result from cellu-
lar hypertrophy (Figure 9B). Again, echocardiographic measurements revealed maintained fractional shorten-
ing, despite LV dilation, while cardiac output and stroke volume were significantly increased (Figure 9, C–E). 
Reflecting the generally weaker phenotype in the SUR2-mutant mice, AI was not observed in any of 5 SUR2wt/AV 
mice, but was observed in 1 of 5 SUR2AV/AV mice, while no littermate controls were affected (data not shown).
Discussion
The pathophysiological effects of  KATP GOF in CS. Autosomal dominant GOF mutations in KCNJ8 and 
ABCC9, the genes encoding the Kir6.1 and SUR2 subunits of  KATP potassium channels, have now been 
established as the genetic basis of  CS (20–24, 27). In addition to hypertrichosis and coarse facial appear-
ance, CS patients are characterized by a constellation of  cardiovascular features, including marked 
cardiomegaly, vascular dilation and tortuosity, low blood pressure, persistence of  fetal circulation, and 
pulmonary hypertension (2–6). While low blood pressure is a directly predictable primary consequence 
of  vascular KATP GOF (Figure 10A), few of  the other features, particularly the cardiac enlargement, 
have a ready explanation, and no direct causal association between the genetic basis and these out-
comes has been established.
Figure 8. Vascular consequences in SUR2wt/AV mice. (A) Representative blood pressures in anesthetized mice show-
ing decreased basal pressures in SUR2wt/AV and SUR2AV/AV mice and blunted response to the KATP channel activator 
pinacidil. (B) Telemetric measurements of mean arterial pressure from ambulatory WT (black), SUR2wt/AV (orange), and 
SUR2AV/AV (red) mice show decreased blood pressure in SUR2AV/AV mice (n = 3 for each genotype). (C) Summary data 
showing basal and pinacidil-reduced systolic (left) and diastolic (right) pressures from anesthetized WT, SUR2wt/AV, 
and SUR2AV/AV mice (n = 6 for WT, 5 for SUR2wt/AV, and 6 for SUR2AV/AV). (D) Isolated descending thoracic aortae show 
progressive dilation in SUR2wt/AV and SUR2AV/AV mice. (E) Aortic diameter derived from 2D sagittal echocardiographic 
imaging at different points around the aortic arch in WT (black), SUR2wt/AV (orange), and SUR2AV/AV (red). STJ, sinotu-
bular junction; AA, ascending aorta; Arch, aortic arch; DA, descending aorta; as shown in inset; n = 3 each). (F) Vessel 
compliance in pressurized carotid arteries of WT (black), SUR2wt/AV (orange), and SUR2AV/AV (red) mice reveal increased 
diameters in mutant mice across full pressure range (n = 4 for WT, 5 for SUR2wt/AV, and 5 for SUR2AV/AV). Statistical 
significance was determined by multiway ANOVA followed by t test pairwise comparison with Bonferroni’s correction for 
multiple comparisons. Adjusted α = 0.008 (B), 0.006 (C), and 0.004 (F). **P < 0.01.
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In generating animal models in which specific CS mutations are introduced into the equivalent endoge-
nous loci in the mouse genome, we can therefore directly test the causal association. The above studies demon-
strate that CS-associated GOF substitutions in both Kir6.1 and SUR2 cause a common constellation of com-
plex cardiovascular features, including increased vascular dilation and compliance, low blood pressure, cardiac 
hypertrophy, and increased cardiac output. As such, our mouse models recapitulate the key cardiovascular 
features observed clinically in CS (2, 3, 6). We observe a clear correlation between the extent of basal vascular 
KATP channel activation and the severity of cardiovascular abnormalities through SUR2
wt/AV, SUR2AV/AV, and 
Kir6.1wt/VM mice (Figure 10B). Notably, this phenotypic severity also correlates with the previously reported 
biophysical effects of these mutations (21, 22, 24). In the compound heterozygous Kir6.1wt/VM/SUR2wt/AV and 
homozygous Kir6.1VM/VM animals, the presumably even stronger molecular phenotype results in early death. 
This precluded detailed assessment of cardiovascular outcomes, but revealed what may be lethal effects of  
resultant gastrointestinal insufficiency. Interestingly, human CS is likely to represent a more severe clinical 
categorization within a spectrum of Kir6.1/SUR2 GOF–associated disorders that also includes acromegaloid 
facial appearance (AFA) syndrome and hypertrichosis with acromegaloid facial features (HAFF) syndrome, 
in which cardiovascular abnormalities are not reported (28). The severity of human disease may directly cor-
relate with effects on molecular function but some of the same mutations have been reported in both CS and 
AFA/HAFF patients, so drawing quantitative phenotype-to-genotype comparisons may prove difficult and 
will require more detailed investigation of multiple mutations (20, 27–29).
Vascular consequences of  KATP GOF — primary CS pathological consequences. That deliberate introduction 
of  these GOF mutations in both ABCC9 and KCNJ8 genes converge to the same pathophysiology conclu-
sively demonstrates that the associated pathologies, as observed in CS, result from changes in the KATP 
channel complex that is generated by SUR2 and Kir6.1 protein association (5, 22). It further indicates 
that the primary consequences must arise in tissue(s) in which both Kir6.1 and SUR2 are expressed. 
Kir6.1 and SUR2 are clearly both expressed in VSMCs (15, 30), but the situation in cardiac myocytes 
Figure 9. Cardiac hypertrophy in SUR2wt/AV mice. (A) Left: Gross heart size is increased in SUR2wt/AV and SUR2AV/AV mice. 
Right: Heart weight normalized to tibia length (HW/TL; mg/mm; n = 10 for WT, 14 for SUR2wt/AV, and 14 for SUR2AV/AV). (B) 
Cell surface area (CSA) measurements from H&E-stained ventricular sections shows cellular hypertrophy in SUR2AV/AV mice 
(n = 45 cells from 3 mice for WT, 162 cells from 3 mice for SUR2wt/AV, and 124 cells from 3 mice for SUR2AV/AV). (C) Fractional 
shortening is unchanged in SUR2wt/AV and SUR2AV/AV mice as determined from M-mode echocardiographic imaging. (D) Car-
diac output is significantly increased in both SUR2wt/AV and SUR2AV/AV mice due to increased stroke volume (E) (n = 4 for WT 
and SUR2wt/AV and 5 for SUR2AV/AV). Statistical significance was determined by multiway ANOVA followed by t test pairwise 
comparison with Bonferroni’s correction for multiple comparisons (adjusted α = 0.017). *P < 0.05.
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is less clear. Most studies indicate that SUR2 is the primary sulfonylurea receptor in the ventricle, and 
that Kir6.2 is the pore-forming subunit (31), evidence for Kir6.1 expression being mostly limited to iso-
lated reports of  expression in conducting tissue (32). That the most severe CS features are present in 
Kir6.1[V65M] mutant mice — in which KATP GOF is observed in VSMCs but not ventricular myocytes 
— therefore points to a cardinal role for a non–cardiac muscle origin of  the ensuing pathophysiology. 
Increased KATP activity in vascular smooth muscle is predicted to decrease cellular excitability and con-
tractility. Consistent with this, SUR2-selective KATP openers acutely decrease vascular tone and lower 
blood pressure in WT animals (33). Enhanced basal vascular KATP activation, as was present in VSMCs 
from both Kir6.1[V65M] and SUR2[A478V] animals, would thus directly lead to reduced vessel contrac-
tility, explaining the lowered blood pressure and reduced response to pinacidil in the whole animal. In 
SUR2[A478V] animals, the maximum KATP overactivity in pinacidil is greater than WT in heterozygous 
and greatest in homozygous animals, yet the blood pressure in the presence of  pinacidil is actually lowest 
in WT and highest in homozygous animals (Figure 8), counter to naive expectations.
In addition, we see that passive vessel compliance is increased in both genotypes. Increased vessel 
compliance may reflect increased elastin production in smooth muscle, as has been reported in response to 
pharmacological activators of  KATP channels in cultured smooth muscle cells (34), and in the rat aorta (35). 
It should be noted that endothelial KATP channels have also been implicated in blood pressure control (36, 
37), and in angiogenesis (38–40). Thus, endothelial dysfunction may also contribute to decreased vascular 
tone and vessel tortuosity in CS, but this remains to be fully elucidated.
AS, AI, and valvular defects are also reported in association with human CS (2, 6). Here we demonstrate 
functional defects in the aortic valve of  Kir6.1wt/VM mice alongside AI and apparent aortic valve stenosis. 
As extensive dilation is observed throughout the vasculature in CS patients (4), and in the Cantu mice, 
we hypothesize that AI may be a direct consequence of  aortic root dilation. Consistent with this, there is 
a marked correlation between aortic diameter and AI in Kir6.1wt/VM mice. The complex combination of  
Figure 10. Progressive cardiovascular consequences of Cantu syndrome. (A) The primary consequence of KATP GOF in 
the vasculature is reduced excitability, leading to functional and structural vasodilation, low blood pressure, and under-
perfusion. Secondarily, this leads to a compensatory cardiac hypertrophy and hypercontractility. (B) These features 
are present in even mild (e.g., SUR2wt/AV) CS models, but are exacerbated in more severe genotypes (e.g., Kir6.1wt/VM and 
SUR2AV/AV). The latter genotypes are associated with premature death, and very early death occurs immediately after 
weaning in the most severe genotypes (e.g., SUR2wt/AV/Kir6.1wt/VM and Kir6.1VM/VM).
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mutually exacerbating AI and AS would be predicted to increase LV preload and afterload, respectively, and 
thence to increase cardiac hypertrophy (see below).
Structural and electrical remodeling in the heart — secondary consequences of  KATP GOF. In contrast to the 
observed vascular manifestations, there are no ready explanations to link KATP GOF and the cardiac fea-
tures of  CS. The naive expectation of  KATP GOF in the heart itself  would be action potential shortening, or 
slowing of  the cardiac rate, either or both of  which will lead to net reduction in cardiac output. However, 
in CS patients (25), and in both Kir6.1[V65M] (Figure 5) and SUR2[A478V] (Figure 9) mutant mice, we 
observe profound cardiac enlargement and enhanced cardiac output. This is despite the different effects of  
the Kir6.1 and SUR2 mutations on ventricular KATP channel properties (Figure 3). Hence we suggest that 
cardiac enlargement is likely to predominantly arise independently of  ventricular KATP activity, and to instead 
be a secondary consequence of  vascular dysfunction (Figure 10A). The enlargement observed in the Cantu 
hearts includes increased LV internal dimensions and wall thickness. This combination is distinct from typical 
eccentric or concentric hypertrophies arising from volume or pressure overload, respectively, and functionally 
resembles physiological, exercise-induced, hypertrophy, in which fractional shortening is maintained (41).
Long-term effects of  CS pathophysiology and implications. The CS combination of  cardiac cellular hyper-
trophy, with chamber and wall enlargement, AI, enhanced cardiac contractility, together with vascular 
dilation and low blood pressure may represent a unique pathophysiological constellation, distinct from 
other commonly defined conditions of  myocardial hypertrophy. Little is yet known about the progressive 
nature of  CS, but it is notable that the majority of  diagnosed patients are children or young adults. Whether 
this reflects the recent recognition of  the condition itself  (the genetic basis was only discovered in the last 
6 years) and the success of  modern palliative therapies, or is an indication of  poor long-term prognosis, 
remains to be elucidated. Cardiac output is elevated in 3-month-old Cantu mice (Figures 5 and 7), but fur-
ther studies will be required to determine whether the various cardiac abnormalities result in a progressive 
functional decline with long-term aging, such as is observed in other forms of  pathological hypertrophy.
First demonstrated in mice almost 20 years ago (42), recognition of  the causal role of  GOF muta-
tions in the Kir6.2/SUR1 proteins in neonatal diabetes (43) has led to dramatically improved under-
standing of  the pathophysiological consequences (44), as well as a revolution in therapy using KATP 
channel–blocking sulfonylurea drugs (45, 46). The Cantu mouse models we describe here will provide 
the opportunity for longitudinal analysis of  CS pathophysiology over time, as well as an appropriate 
preclinical model in which to test the efficacy of  KATP inhibitors (such as sulfonylureas) or other potential 
therapies, for what is currently an untreatable syndrome. Moreover, as these mice now confirm a causal 
link between KATP GOF mutations and a host of  complex cardiovascular outcomes, they point the way to 
future studies aimed at understanding the broader consequences of  pathophysiological changes in KATP 
channel resulting from nongenetic causes, such as altered cell signaling.
Methods
Study approval
Studies were performed in compliance with the standards for the care and use of  animal subjects defined in 
the NIH Guide for the Care and Use of  Laboratory Animals (33) and were reviewed and approved by the 
Washington University Institutional Animal Care and Use Committee.
CRISPR/Cas9 genome editing
Using CRISPR/Cas9–mediated genome engineering technology (47), we generated knockin mice carrying 
human GOF mutations in the ABCC9 or KCNJ8 genes, which encode the accessory SUR2 and the pore-form-
ing Kir6.1 subunits of  the KATP channel, respectively. The guide RNA (gRNA) target sequences were predicted 
using the MIT CRISPR design tool (http://crispr.mit.edu). abcc9 gRNA (5′ CATTGCCACGAAGCTGGC-
GG 3′) or kcnj8 gRNA (5′ ACGCCACTTCAGGTCTACCA 3′) were subcloned into BbsI-digested plasmid 
pX330 (Addgene, 42230). sgRNA activity was validated in vitro by transfection of  N2A cells using Roche 
Xtremegene HP, followed by T7E1 assay (NEB). T7 sgRNA template and T7 Cas9 template were prepared 
by PCR amplification and gel purification, followed by RNA in vitro transcription with the MEGAshortscript 
T7 kit (gRNA) or the T7 mMessage mMachine Ultra kit (Cas9). After transcription, RNA was purified with 
the Megaclear kit (Life Technologies). Single-stranded oligodeoxynucleotide (ssODN) donor DNAs (200 nt) 
with the appropriate mutation centered within the ODN were synthesized by IDT as ultramer ODNs.
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B6CBA F1/J female mice (3–4 weeks old; Jackson Laboratory) were superovulated and mated 
overnight with B6CBA F1/J male mice (>7 weeks old). Zygotes were harvested from the ampullae of  
superovulated females and placed in potassium-supplemented simplex optimized medium (KSOM; 
MR106D) before microinjection. Microinjection of  the Cas9, sgRNA, and ssDNA template (at a 
final concentration of  50 ng/μl Cas9 WT RNA, 25 ng/μl gRNA, and 20 ng/μl ssODN DNA) was 
performed in flushing holding medium (FHM; MR-024-D; EmbryoMax; Millipore). After injection, 
zygotes were incubated at 5.5% CO2 at 37°C for 2 hours, and surviving embryos were transferred to 
ICR recipient mice by oviduct transfer. Founders were identified using Qiagen pyrosequencer and 
Pyromark Q96 2.5.7 software. We identified 12 positive founder animals carrying CS mutation mouse 
SUR2[A476V] (equivalent to human SUR2[A478V]), and 2 positive founder animals carrying the CS 
mutation Kir6.1[V65M]. All founders were viable and fertile. Successful mutation of  founder (F0) 
mice was verified by Sanger sequencing of  genomic DNA and mutant mice were subsequently crossed 
with C57BL/6J mice to generate heterozygous F1 Kir6.1wt/VM and SUR2wt/AV lines. PCR was used to 
generate amplicons of  KCNJ8 and ABCC9 spanning >1 kb on either side of  the introduced mutation, 
from gDNA isolated from mouse tails, and resultant PCR products were sequenced to confirm absence 
of  unintended additional mutations. After verification, one F1 animal from one line of  each genotype 
was selected and further crossed against C57BL/6J to generate F2 heterozygous animals, which were 
intercrossed to generate F3 heterozygous and heterozygous as well as WT littermates that were used 
in experiments.
Patch-clamp electrophysiology
Isolated VSMCs. Mice were anesthetized with 2.5% avertin (10 ml/kg, i.p.; Sigma-Aldrich) and the 
descending aorta was rapidly dissected and placed in ice-cold physiological saline solution (PSS) contain-
ing (in mM) 134 NaCl, 6 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES, and 10 glucose, with pH adjusted to 7.4 with 
NaOH. Smooth muscle cells were enzymatically dissociated in dissociation solution containing (in mM) 
55 NaCl, 80 sodium glutamate, 5.6 KCl, 2 MgCl2, 10 HEPES, and 10 glucose, pH 7.3 with NaOH, then 
placed into dissociation solution containing papain μg/ml 12.5, 1 mg/ml dithioerythritol, and 1 mg/ml 
BSA for 25 minutes (at 37°C), before transfer to dissociation solution containing 1 mg/ml collagenase 
(type H/F = 1:2), and 1 mg/ml BSA for 5 minutes (at 37°C). Cells were dispersed by gentle trituration 
using a Pasteur pipette, plated onto glass coverslips on ice, and allowed to adhere for more than 1 hour 
before transfer to the recording chamber.
Whole-cell KATP currents were recorded using an Axopatch 200B amplifier and Digidata 1200 (Molecu-
lar Devices). Recordings were sampled at 3 kHz and filtered at 1 kHz. Currents were initially measured at a 
holding potential of  –70 mV in a high-Na+ bath solution containing (in mM) 136 NaCl, 6 KCl, 2 CaCl2, 1 
MgCl2, 10 HEPES, and 10 glucose, with pH adjusted to 7.4 with NaOH before switching to a high-K
+ bath 
solution (140 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES, and 10 glucose, with pH adjusted to 7.4 with KOH) in the 
absence and presence of  pinacidil and glibenclamide as indicated. The pipette solution contained (in mM) 
110 potassium aspartate, 30 KCl, 10 NaCl, 1 MgCl2, 10 HEPES, 0.5 CaCl2, 4 K2HPO4, and 5 EGTA, with 
pH adjusted to 7.2 with KOH.
Isolated ventricular myocytes. Adult mice were anesthetized using 2.5% Avertin (10 ml/kg), and the heart 
and ascending aorta were removed and immersed in ice-cold calcium-free Wittenberg Isolation Medium 
(WIM; in mM): 116 NaCl, 5.4 KCl, 8 MgCl2, 1 NaH2PO4, 1.5 KH2PO4, 4 NaHCO3, 12 glucose, 21 HEPES, 
2 glutamine plus essential vitamins (GIBCO), and essential amino acids (GIBCO) (pH 7.40). The heart was 
cannulated via the aorta and Langendorff  perfused with WIM for 5 minutes at 37°C, followed by 20-min-
ute perfusion of  WIM supplemented with 270 units/ml of  collagenase type 2 (Worthington Biochemical) 
and 10 μM CaCl2 at 37°C. The heart was then transferred to WIM containing 50 mg/ml BSA, 12.5 mg/ml 
taurine, and 150 μM CaCl2, and ventricular tissue was manually dissociated using forceps before single-cell 
dissociation by trituration with a fire-polished Pasteur pipette.
Inside-out patch-clamp recordings were made in symmetrical KINT solution that contained (in mM) 
140 KCl, 10 HEPES, 1 EGTA (pH 7.4 with KOH). Varying MgATP concentrations were applied using 
a Dynaflow Resolve perfusion chip (Cellectricon). MgCl2 was added to each solution to achieve a free 
[Mg2+] of  0.5 mM according to calculations using CaBuf  (Katholieke Universiteit Leuven). Membrane 
currents were sampled at 3 kHz, filtered at 1 kHz, at a holding potential of  –50 mV using an Axopatch 
700B amplifier and Digidata 1200. KATP channel currents in solutions of  varying nucleotide concentrations 
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were normalized to the basal current in the absence of  nucleotides and dose-response data were fit with a 
4-parameter Hill fit according to the equation: Normalized current = Imin + (Imax – Imin)/(1 + ([X]/IC50)H), 
where the current in Kint = Imax = 1, Imin is the normalized minimum current observed in MgATP, [X] refers 
to the concentration of  MgATP, IC50 is the concentration of  half-maximal inhibition, and H denotes the 
Hill coefficient.
Arterial compliance
After mice were euthanized under isoflurane anesthesia, the left common carotid arteries of  3-week-old 
mice were excised and placed in PSS containing 130 mM NaCl, 4.7 mM KCl, 1.18 mM MgSO4-7H2O, 
1.17 mM KH2PO4, 14.8 mM NaHCO3, 5.5 mM dextrose, and 0.026 mM EDTA (pH 7.4). The vessels 
were then cleaned from surrounding fat, mounted on a pressure arteriograph (Danish Myo Technology) 
and maintained in PSS at 37°C. Vessels were visualized with an inverted microscope connected to a 
charged-coupled device camera and a computerized system, which allows continuous recording of  ves-
sel diameter. Intravascular pressure was increased from 0 to 175 mmHg by 25-mmHg increments and 
the vessel outer diameter was recorded at each step (12 seconds per step). The average of  3 measure-
ments at each pressure was reported.
Blood pressure measurement
Mice were anesthetized with 1.5% inhaled isoflurane and restrained on a heating pad to maintain body 
temperature. A 2- to 3-mm incision was made in the midline of  the neck; the thymus and muscle were sepa-
rated to expose the right carotid artery. A Millar pressure transducer (model SPR-671) was carefully insert-
ed into the right carotid artery and moved to the ascending aorta. Systolic blood pressure, diastolic blood 
pressure, and heart rate were recorded using the PowerLab data acquisition system (ADInstruments), and 
data were analyzed using LabChart 7 (ADInstruments). For blood pressure measurements in conscious 
mice, a radio-telemetry pressure transmitter (Data Science International, DSI) was surgically inserted into 
the left carotid artery and moved to the ascending aorta, where blood pressures in day and night were 
recorded by DSI data acquisition system after mice recovered from surgery.
Heart weight measurement and histology
Mice were anesthetized with 2.5% Avertin and hearts were excised and rinsed with PBS that contained 
(in mM) 137 NaCl, 2.7 KCl, 10 Na2HPO4, and KH2PO4 (pH 7.4 with NaOH). The hearts were arrested 
in diastole with 10% KCl, and blotted to remove excess liquid. Hearts were then weighed and weight 
was normalized to tibia length. After weighing, the hearts were fixed in 10% buffered formalin for 24 
hours, and embedded in paraffin. Sections (3 μm) were cut and stained with H&E for the morphomet-
ric analysis.
Echocardiography
Echocardiography was performed using a Vevo 2100 Imaging System (VisualSonics) equipped with a 
30-MHz linear-array transducer according to previously published methods (48–50). Cardiac images 
were obtained by a handheld technique using 100 mg/kg i.p. tribromoethanol anesthetic; aortic imag-
es were obtained under 1.5% inhaled isoflurane. M-mode images were used to make LV dimensional 
measurements.  Quantitative image analysis was also performed using a speckle-tracking algorithm to 
obtain volumetric and strain data. Sagittal 2D images of  the aortic arch were used to measure aortic 
diameters at multiple levels and to obtain Doppler images for pulse wave velocity measurements.
Statistics
Unless otherwise noted, data were tested for statistical significance using t test or multiway ANOVA with 
Bonferroni’s correction as applicable, and are presented as mean ± SEM. Unless otherwise noted, signifi-
cance is denoted as P < 0.05.
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